A related study reveals the long-term outcomes of the main ingredient in Ozempic and Wegovy.
New research has found weight loss drug Wegovy can produce significant results for at least four years of treatment. The drug has also been found to deliver cardiovascular benefits in overweight and obese patients irrespective of the weight lost.Wegovy is an injectable prescription drug that was approved by the FDA in 2021 for chronic weight loss management.
The participants were overweight or obese with a history of cardiovascular disease but not diabetes and were given either Semaglutide or placebo for the study period.On average, patients on Semaglutide lost 10 percent of their body weight and roughly three inches around their waistline during the roughly four-year period. This was compared to a weight loss of 1.5 percent and 0.5 inches around the waist in the placebo group.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight Loss Drug Zepbound May Help Sleep Apnea, Study FindsLisa Mosconi, PhD, is a neuroscientist, neuro-nutritionist, and an expert on women’s brain health and longevity. Follow her tips and advice for a healthy brain.
Read more »
Eli Lilly's weight loss drug reduces sleep apnea, study showsEli Lilly noted that tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults that have both obstructive sleep apnea and obesity.
Read more »
Cognitive factors may influence attrition, weight loss, and weight maintenance.Specific cognitive factors are associated with attrition, weight loss, and maintenance, but are not usually addressed by the treatment of obesity
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Read more »